Could interleukin-33 and its suppressor of tumorigenicity 2 (ST2) receptor have a role in cervical human papillomavirus (HPV) infections?

References

• Araldi RP, Assaf SMR, Carvalho RF, et al. Papillomaviruses: a systematic review. Genet Mol Biol. 2017;40:1.
   PubMed Web of Science ®Google Scholar
• Gadducci A, Barsotti C, Cosio S, et al. Smoking habit, immune suppression, oral contraceptive use, and hormone replacement therapy use and cervical carcinogenesis: a review of the literature. Gynecol Endocrinol. 2011;27:597–604.
   PubMed Web of Science ®Google Scholar
• Duerr A, Kieke B, Warren D, et al. Human papillomavirus-associated cervical cytologic abnormalities among women with or at risk of infection with human immunodeficiency virus. Am J Obstet Gynecol. 2001;184:584–590.
   Web of Science ®Google Scholar
• Nayki C, Nayki U, Kulhan M, et al. The effect of diabetes on ovaries in a rat model: the role of interleukin-33 and apoptosis. Gynecol Endocrinol. 2017;33:708–711.
   PubMed Web of Science ®Google Scholar
• Haukioja A, Asunta M, Söderling E, et al. Persistent oral human papillomavirus infection is associated with smoking and elevated salivary immunoglobulin g concentration. J Clin Virol. 2014;61:101–106.
   PubMed Web of Science ®Google Scholar
• Rositch AF, Koshiol J, Hudgens M, et al. Patterns of persistent genital human papillomavirus infection among women worldwide: a literature review and meta-analysis. Int J Cancer. 2013;133:1271–1285.
   PubMed Web of Science ®Google Scholar
• Oh HY, Seo SS, Kim MK, et al. Synergistic effect of viral load and alcohol consumption on the risk of persistent high-risk human papillomavirus infection. PLoS One. 2014;9:e104374.
   PubMed Web of Science ®Google Scholar
• Xi LF, Koutsky LA, Castle PE, et al. Relationship between cigarette smoking and human papilloma virus types 16 and 18 DNA load. Cancer Epidemiol Biomark Prev. 2009;18:3490–3496.
   PubMed Web of Science ®Google Scholar
• Peng S, Trimble C, Wu L, et al. HLA-DQB1*02-restricted HPV-16 E7 peptide-specific CD4+ T-cell immune responses correlate with regression of HPV-16-associated high-grade squamous intraepithelial lesions. Clin Cancer Res. 2007;13:2479–2487.
   PubMed Web of Science ®Google Scholar
• Wank R, Thomssen C. High risk of squamous cell carcinoma of the cervix for women with HLA-DQw3. Nature. 1991;352:723–725.
   PubMed Web of Science ®Google Scholar
• Zoodsma M, Nolte IM, Schipper M, et al. Analysis of the entire HLA region in susceptibility for cervical cancer: a comprehensive study. J Med Genet. 2005;42:e49.
   PubMed Web of Science ®Google Scholar
• Liaw KL, Hildesheim A, Burk RD, et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis. 2001;183:8–15.
   PubMed Web of Science ®Google Scholar
• Rousseau MC, Pereira JS, Prado JC, et al. Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection. J Infect Dis. 2001;184:1508–1517.
   PubMed Web of Science ®Google Scholar
• Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2:342–350.
   PubMed Web of Science ®Google Scholar
• Sato S, Yanagawa Y, Hiraide S, et al. Cyclic AMP signaling enhances lipopolysaccharide sensitivity and interleukin-33 production in RAW264.7 macrophages. Microbiol Immunol. 2016;60:382–389.
   PubMed Web of Science ®Google Scholar
• Evans MF, Adamson CS, Papillo JL, et al. Distribution of human papillomavirus types in thinprep papanicolaou tests classified according to the Bethesda 2001 terminology and correlations with patient age and biopsy outcomes. Cancer. 2006;106:1054–1064.
   PubMed Web of Science ®Google Scholar
• Lamkanfi M, Dixit VM. IL-33 raises alarm. Immunity. 2009;31:5–7.
   PubMed Web of Science ®Google Scholar
• Scott ME, Shvetsov YB, Thompson PJ, et al. Cervical cytokines and clearance of incident human papillomavirus infection: Hawaii HPV cohort study. Int J Cancer. 2013;133:1187–1196.
   PubMed Web of Science ®Google Scholar
• Oboki K, Ohno T, Kajiwara N, et al. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc Natl Acad Sci USA. 2010;107:18581–18586.
   PubMed Web of Science ®Google Scholar
• Xu D, Chan WL, Leung BP, et al. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med. 1998;187:787–794.
   PubMed Web of Science ®Google Scholar
• Rank MA, Kobayashi T, Kozaki H, et al. IL-33-activated dendritic cells induce an atypical TH2-type response. J Allergy Clin Immunol. 2009;123:1047–1054.
   PubMed Web of Science ®Google Scholar
• Kurowska-Stolarska M, Kewin P, Murphy G, et al. IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. J Immunol. 2008;181:4780–4790.
   PubMed Web of Science ®Google Scholar
• Komai-Koma M, Xu D, Li Y, et al. IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol. 2007;37:2779–2786.
   PubMed Web of Science ®Google Scholar
• Komai-Koma M, Gilchrist DS, McKenzie AN, et al. IL-33 activates B1 cells and exacerbates contact sensitivity. J Immunol. 2011;186:2584–2591.
   PubMed Web of Science ®Google Scholar
• Schneider E, Petit-Bertron AF, Bricard R, et al. IL-33 activates unprimed murine basophils directly in vitro and induces their in vivo expansion indirectly by promoting hematopoietic growth factor production. J Immunol. 2009;183:3591–3597.
   PubMed Web of Science ®Google Scholar
• Kropf P, Herath S, Klemenz R, et al. Signaling through the T1/ST2 molecule is not necessary for Th2 differentiation but is important for the regulation of type 1 responses in nonhealing Leishmania major infection. Infect Immun. 2003;71:1961–1971.
   PubMed Web of Science ®Google Scholar
• Jones LA, Roberts F, Nickdel MB, et al. IL-33 receptor (T1/ST2) signalling is necessary to prevent the development of encephalitis in mice infected with Toxoplasma gondii. Eur J Immunol. 2010;40:426–436.
   PubMed Web of Science ®Google Scholar
• Miyagaki T, Sugaya M, Yokobayashi H, et al. High levels of soluble ST2 and low levels of IL-33 in sera of patients with HIV infection. J Invest Dermatol. 2011;131:794–796.
   PubMed Web of Science ®Google Scholar
• Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov. 2008;7:827–840.
   PubMed Web of Science ®Google Scholar
• Baumann C, Bonilla WV, Frohlich A, et al. T-bet- and STAT4-dependent IL-33 receptor expression directly promotes antiviral Th1 cell responses. Proc Natl Acad Sci USA. 2015;112:4056–4061.
   PubMed Web of Science ®Google Scholar